CTLA4 and non-small cell lung carcinoma: NLR is a marker for the general immune response to various stress stimuli, and it is shown to predict outcome among NSCLC and melanoma patients treated with PD-1 inhibitors [78,81,82,83,84], and CTLA-4 antibodies [78,83,85,86].